Zobrazeno 1 - 10
of 35
pro vyhledávání: ''
Autor:
Helene C. Highbarger, Zonghui Hu, Alice K. Pau, Dean Follmann, Harsha Somaroo, Robin L. Dewar, Judith N. Dlamini
Publikováno v:
Pharmacotherapy. 31:158-163
Study Objective. To evaluate the effect of a previous single dose of nevirapine given to prevent mother-to-child transmission of human immunodeficiency virus (HIV) on virologic and immunologic measures after 6 months of an antiretroviral regimen cont
Publikováno v:
Pharmacotherapy. 31:39-51
Study Objective. To compare the efficacy of biologic disease-modifying antirheumatic drugs (DMARDs) versus placebo with or without methotrexate, in treating rheumatoid arthritis. Design. Comparative effectiveness analysis using an indirect treatment
Autor:
Siegfried Schmidt, Julie A. Johnson, Stephen T. Turner, Jonathan J. Shuster, Reginald F. Frye, Hrishikesh Navare, Karen Hall, Rhonda M. Cooper-DeHoff
Publikováno v:
Pharmacotherapy. 30:872-878
Study Objective—To evaluate whether the level of systemic exposure to atenolol explains observed interindividual differences in adverse metabolic responses. Design—Open-label, prospective, pharmacokinetic pilot substudy of the Pharmacogenomic Eva
Publikováno v:
Pharmacotherapy. 30:812-817
Study Objectives. To assess the effectiveness of prophylactic albumin for the prevention of ifosfamide-induced encephalopathy (IIE), and to describe risk factors for IIE and investigate the predictive potential of a novel risk-stratification model fo
Autor:
J. Richard Thompson
Publikováno v:
Pharmacotherapy. 30:4S-9S
Practice guidelines for hepatic encephalopathy were developed and published in 2001 for overall management in adults. Hepatic encephalopathy is caused by nitrogenous substances from the gastrointestinal tract that adversely affect brain function. Hep
Publikováno v:
Pharmacotherapy. 30:442-452
Study Objective. To compare the cardiovascular and metabolic effects of medroxyprogesterone acetate (MPA) with those of conjugated equine estrogen (CEE) as single-hormone therapies in women who underwent hysterectomy with bilateral ovariectomy. Desig
Publikováno v:
Pharmacotherapy. 30:136-143
Study Objective. To examine the effect of telavancin, a lipoglycopeptide antibiotic with potent gram-positive activity, on the pharmacokinetics of midazolam, a cytochrome P450 (CYP) 3A probe substrate. Design. Phase I, randomized, double-blind, place
Autor:
Tracey O'Connor, Ellen Kossoff
Publikováno v:
Pharmacotherapy. 29:993-996
Paclitaxel, a microtubule stabilizer, is an effective agent for treating cancer of the breast, ovary, head and neck, and lung. Because paclitaxel is insoluble in water, it is formulated with the micelle-forming Cremophor EL. Neurologic toxicity is we
Publikováno v:
Pharmacotherapy. 28:691-698
Study Objective. To evaluate the steady-state pharmacokinetics and pharmacodynamics of meropenem 500 mg every 6, 8, and 12 hours, based on renal function, in hospitalized patients. Design. Prospective, open-label, steady-state pharmacokinetic study.
Autor:
Margaret Connolly, William P. Forbes, Doug Bettenhausen, Helen S Pentikis, Carol Braun Trapnell
Publikováno v:
Pharmacotherapy. 27:1361-1369
Study Objective. To evaluate the potential of rifaximin, an oral nonabsorbed (< 0.4%) structural analog of rifampin, to induce human hepatic and/or intestinal cytochrome P450 (CYP) 3A enzymes, with use of a known CYP3A probe, midazolam. Design. Prosp